Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Notes Impressive Advancement in Cannabis, Functional Mushrooms, Psilocybin Spaces
June 3, 2021
Pure Extracts’ BC facility is fully operational, ready to meet increasing demand for cannabis-based gummies, vapes, white label products Company’s involvement in functional, psychoactive mushrooms space is also gaining steam Pure Extracts’ current R&D focus is on psychoactive mushroom compounds Although the global pandemic extended its sales cycle, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin
June 3, 2021
Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials The company intends to contribute to the growing body of research through academic collaborations […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) to Present at Upcoming H.C. Wainwright Psychedelics Conference
June 2, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, has announced that it will be presenting at H.C. Wainwright & Co.’s Psychedelics in Psychiatry and Beyond conference. The virtual event will be held on June 17, 2021. At the […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances
May 28, 2021
Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021 Tryp’s scientific and executive team […]
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio
May 26, 2021
Company files 12th patent to strengthen proprietary IP program Cybin believes treatments can decrease costs, increase access to important therapeutics Patent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnership with CDMO Alcami for Exclusive Product Formulation
May 25, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways, has entered into an agreement with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (“CDMO”). The agreement marks Tryp’s next step in the proprietary manufacturing, formulation and […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts
May 24, 2021
Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering […]
InvestorNewsBreaks – Enveric Biosciences (NASDAQ: ENVB) Enters Strategic Agreement to Acquire MagicMed Industries
May 24, 2021
Enveric Biosciences (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced its entry into a definitive agreement to acquire MagicMed Industries Inc. in an all-stock transaction. MagicMed is a privately held biotechnology company focused on creating a library of novel derivative psychedelic molecules such […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Brings Best-in-Class Team to Psychedelics Development
May 21, 2021
NEW YORK, May 21, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Wall Street Unicorns in Process of Changing the Healthcare Landscape.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/QOAcO Most people may not recognize some of the […]
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast featuring Brent Bedford, President, Chairman & CEO of Perpetual Industries Inc.
May 20, 2021
LOS ANGELES, May 20, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates
May 20, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Diversified Pipeline to Psychedelic Revival
May 19, 2021
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Wall Street Unicorns in Process of Changing the […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder
May 18, 2021
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board (“IRB”) at the University of the West Indies Hospital in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation (“CYB001”) in a Phase II clinical trial for patients suffering with major […]
Perpetual Industries Inc. (PRPI) CEO Talks Strategy, Updates in Video Interview
May 17, 2021
“Perpetual Industries is designed to be an incubator for those ideas of innovation that will make things better in our lives,” says CEO PRPI currently focused on developing XYO proprietary balancing technology XYO ready for commercialization; company developing a vertical axis wind turbine and a domestic washing machine Perpetual Industries’ (OTC: PRPI) CEO Brent Bedford […]
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update
May 14, 2021
April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that’s not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth A series of recent analyst reports bodes well for […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article
May 14, 2021
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders
May 13, 2021
Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia The company is also developing a clinical trial to address the needs of […]
InvestorNewsBreaks – Numinus Wellness Inc. (TSX.V: NUMI), Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) Partner in Pre-Clinical Trial Application for Psilocybin Extract
May 12, 2021
Numinus Wellness (TSX.V: NUMI), a mental-health-care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, has joined with Optimi Health Corp.(CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) to submit an all-natural psilocybin extract to Health Canada for pre-clinical trial approval. Optimi Health is the developer of a vertically integrated functional mushroom brand focused on the health […]
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities
May 10, 2021
Company committed to building presence in U.S. and Europe to advance mission of improving mental health care New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry New leaders bring broad experience, deep insight to their new roles Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix
May 10, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics
May 7, 2021
Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disorders Tryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the […]
InvestorBrandNetwork Announces Gamechangers LIVE Interview with XPhyto Therapeutics Corp. CEO and Director Hugh Rogers
May 6, 2021
LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTC:XPHYF), recently appeared on Gamechangers LIVE, a podcast series putting a spotlight on individuals who are gamechangers in their fields and […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders
May 4, 2021
Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas Tryp has partnered with the University of Florida to conduct a Phase […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Releases Corporate Update
May 3, 2021
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has provided a corporate update regarding its cannabis, functional mushroom and psilocybin business operations. The update notes that, in spite of COVID-19, its Pemberton, British Columbia facility is fully operational […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training
May 3, 2021
Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’
April 30, 2021
Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways The company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas) Through its PFN(TM) program, the company is […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Second-Quarter 2021 Financial Numbers
April 30, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs, has reported its interim financial results and business highlights for the three- and six-month periods ended Feb. 28, 2021. Highlights of the report include […]
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Retail Business to Bloom This Spring With Production of 50,000 Blister Packs
April 28, 2021
PULL starts production of roughly 50,000 blister pack gummies using Taste-T LLC’s successful proprietary manufacturing system Global CBD gummies market size estimated to grow at CAGR of 31.9% until 2025 PULL estimates $200,000 in revenue from initial batch, plans to produce three additional non-THC SKUs with varying levels of ultra-high potency CBD Pure Extracts Technologies […]
InvestorNewsBreaks – PsyBio Therapeutics Corp. (TSXV: PSYB) Expands Collaboration with Miami University to Expedite FDA IND Submission
April 26, 2021
PsyBio (TSXV: PSYB), a biotechnology company pioneering the next generation of targeted psychoactive medications, today announced that it has amended its master sponsored agreement with Miami University based in Oxford, Ohio. The amended agreement extends and expands the research efforts of the laboratory of Dr. J. Andrew Jones in the Department of Chemical, Paper and […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Advancement of IND-Enabling Studies of Psychedelic Molecules for IND Applications
April 13, 2021
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has plans to advance the preclinical work for two of its deuterated tryptamine development candidates: its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004. In the announcement, the company noted that the planned studies are part of […]
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Letter of Intent to Co-Develop Psychedelic Mushroom-Based Psilocybin Formulations
April 12, 2021
PULL signs Letter of Intent with Psyence Group to co-develop extraction techniques for production of psilocybin drug formulations Psyence is one of world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility PULL operates best-in-class processing infrastructure under Standard Processing License by Health Canada Near term milestones include Canada-based human clinical […]
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates
April 6, 2021
Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters LOI for Psilocybin Extraction, Development of Formulations
March 31, 2021
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has inked a letter of intent (“LOI”) to form a joint venture (“JV”) with Psyence Group Inc. (CSE: PSYG). The agreement with Psyence, one of the world’s first psychedelic mushroom companies […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations
March 30, 2021
Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former […]
Perpetual Industries Inc. (PRPI) Is ‘One to Watch’
March 26, 2021
Perpetual Industries Inc. is expanding expertise and knowledge of energy-efficient technologies through the development of low-cost, green energy solutions for various industries The company’s R&D portfolio includes its proprietary XYO Balancing Technology, WindSilo, the XYO Washing Machine and Green Energy Mining (“GEM”) Systems The proprietary XYO Balancing Technology is optimized to eliminate vibration in a […]
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution
March 26, 2021
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Science Drives Surging Interest in Psychedelic Therapeutics.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/3IBl7 Psilocybins are a hallucinogenic substance found in certain types of mushroom, dubbed magic mushrooms, and […]
Cybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges
March 25, 2021
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Science Drives Surging Interest in Psychedelic Therapeutics,” please visit: https://nnw.fm/3IBl7 The push […]
MagicMed Industries Inc. Featured in Virtual Coverage of Investor Summit Group’s Q1 Virtual Summit
March 22, 2021
MagicMed Industries Inc. intends to partner with pharmaceutical and other companies to develop and commercialize psychedelic-derived pharmaceutical candidates. MagicMed’s psychedelic derivatives library, the Psybrary™, is intended to be an essential building block from which industry can develop new patented products. The initial focus of the Psybrary™ is on psilocybin and DMT derivatives, and the Psybrary™ […]
Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Subsidiary Pure Mushrooms Corp. Submits Application to Health Canada for a Dealer’s License
March 22, 2021
Pure Extracts Technologies Corp.’s subsidiary Pure Mushrooms Corp. has submitted an application to Health Canada for a Dealer’s License Award of a Dealer’s License will enable company to procure controlled substances, conduct research, carry out business-to-business sales Pure Extracts has recently commenced a study into psilocybin-based active treatments, with research set to be carried out […]
InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Releases Refiled Financial Statements, MD&A
March 12, 2021
Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announced that it has refiled its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three- and six-month periods ended March 31, 2020, following a review by the British Columbia Securities Commission. In its earlier reports of the periods mentioned, Champignon reported intangible assets […]